OCEA

Ocean Biomedical, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website oceanbiomedical.com
Employees(FY) -
ISIN US67644C1045

Performance

+2.17%

-7.6%

-32.91%

-54.2%

+0.62%

YTD

+11.74%

Profile

Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases. The company is developing an antibody therapeutic product candidate inhibiting Chi3l1, and a bi-specific antibody product candidate inhibiting Chi3l1 plus PD-1 and CTLA-4 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. It is also developing three product candidates based on the WPDS platform, including a malaria vaccine candidate; a humanized mAb malaria therapeutic candidate targeting Plasmodium falciparum glutamic-acid-rich protein (PfGARP); and a small molecule malaria therapeutic candidate targeting PfGARP. The company is based in Providence, Rhode Island. Ocean Biomedical, Inc. operates as a subsidiary of Poseidon Bio, LLC.

Advanced Technical Analysis

Technical Analysis of OCEA 2024-12-20

The stock indicators reflect a mixed sentiment, with the Moving Average Score at 30 indicating a bearish outlook, while the Oscillators Score at 60 suggests bullish momentum. Overall, the Technical Score of 45 reinforces a neutral stance, highlighting uncertainty in the market direction.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of OCEA

Stock Rank

Recent News & Updates

2024-11-22 03:45
Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q(Globenewswire)
2024-10-22 04:45
Ocean Biomedical, Inc. Announces Receipt of Nasdaq Staff Determination Letter(Globenewswire)
2024-10-14 19:30
Molecure (WSE: MOC) and Nasdaq-listed biotechnology company Ocean Biomedical (NASDAQ: OCEA) sign an exclusive licensing agreement for the development and commercialization of selective YKL-40 inhibitors.(Globenewswire)
2024-09-30 20:01
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Publication of New Data Deepening Understanding of Novel Cancer Immunotherapy Treatment Approach Targeting CHI3L1 and its Ability to Inhibit Anti-tumor and Related Tissue Remodeling Responses(Globenewswire)
2024-08-26 20:01
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Issued for PfGARP Malaria Antibodies Central to Company's Malaria Treatment and Prevention Platforms(Globenewswire)
2024-08-23 04:30
Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q(Globenewswire)
2024-06-11 19:46
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday(Investorplace)
2024-06-04 19:01
Ocean Biomedical (NASDAQ: OCEA) Congratulates Joint Venture Partner, Virion Therapeutics, on Positive Immunogenicity Results from Their Lead Checkpoint Modifier-Containing Immunotherapy, VRON-0200, for HBV Functional Cure, at EASL 2024(Globenewswire)
2024-05-29 19:44
Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q(Globenewswire)
2024-05-22 23:53
OCEA Stock Earnings: Ocean Biomedical Reported Results for Q3 2023(Investorplace)
2024-05-15 20:01
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Allowance for Malaria Antibodies That Have Potential Capability to Protect Against Infection and Treat Severe Disease(Globenewswire)
2024-04-24 04:51
Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K(Globenewswire)
2024-03-28 01:15
13 Hot Stocks to Invest in According to Wall Street Analysts(Insidermonkey)
2024-03-27 20:01
Ocean Biomedical (NASDAQ: OCEA) Congratulates JV Partner, Virion Therapeutics, on Promising First-Ever Human Phase 1B Clinical Safety Data for Their Lead Checkpoint Modifier-Containing Immunotherapy for HBV Functional Cure, at Global APASL(Globenewswire)
2024-03-24 03:52
5 Best Biotech Penny Stocks to Invest In(Insidermonkey)
2024-03-04 19:30
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments(Globenewswire)
2024-02-28 19:01
Ocean Biomedical (NASDAQ: OCEA) Announces Joint Venture Partner, Virion Therapeutics to Present Their First Clinical Study Data as an Accepted Late Breaker Presentation at 2024 APASL Global Liver Meeting(Globenewswire)
2023-12-04 20:45
EXCLUSIVE: Ocean Biomedical Announces Publication of Breast Cancer Research On New Tumor Suppression Pathway for Proprietary Antibody(Yahoo Finance)
2023-12-04 19:15
Ocean Biomedical, Inc. Announces Publication of Groundbreaking Breast Cancer Research Uncovering a New Tumor Suppression Pathway for Its Proprietary Anti-Chi3L1 Antibody(Globenewswire)
2023-11-29 04:41
Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q(Globenewswire)
2023-11-13 19:01
Ocean Biomedical (NASDAQ: OCEA) Announces Positive Preclinical Oncology Data for VRON-0300, Presented at SITC 2023 Annual Meeting, and Clinical Updates by 50/50 Joint Venture Partner Virion Therapeutics(Globenewswire)
2023-10-31 19:00
Presenting on the Emerging Growth Conference 64 Day 2 on November 2 Register Now(Globenewswire)
2023-10-30 19:00
Presenting on the Emerging Growth Conference 64 Day 1 on November 1 Register Now(Globenewswire)
2023-10-25 18:30
EXCLUSIVE: Ocean Biomedical's JV Partner Virion Therapeutics Dosed First Patients In Novel Immunotherapy Study For Chronic Hepatitis B(Yahoo Finance)
2023-10-25 17:30
Virion Therapeutics and Joint Venture Partner, Ocean Biomedical (NASDAQ: OCEA), Announce First Patients Dosed with Novel Immunotherapy Evaluating a Functional Cure for Chronic Hepatitis B Virus Infection(Prnewswire)
2023-10-25 17:30
Ocean Biomedical (NASDAQ: OCEA) Announces First Patients Dosed by Joint Venture Partner Virion Therapeutics in Phase 1b Study of Novel Immunotherapy for Chronic Hepatitis B Virus Infection(Globenewswire)
2023-10-23 18:30
Ocean Biomedical (NASDAQ: OCEA) Announces $1 Million Falk Award for Malaria Drug Candidate Addressing Evolving Resistance to Artemisinin-Based Therapeutics to Chief Scientist Dr. Jonathan Kurtis(Globenewswire)
2023-10-16 20:01
Ocean Biomedical (NASDAQ: OCEA) Announces Enrollment of Patients for Phase 1b Study for Chronic Hepatitis B Treatment in 50-50 Joint Venture with Virion Therapeutics(Globenewswire)
2023-10-11 20:01
Ocean Biomedical and Virion Therapeutics Form Joint Venture Supporting Multi-National, First-In-Humans Clinical Chronic Hepatitis B Study: Now Enrolling, With Goal of a Functional Cure for a Disease Affecting 300+ Million Patients Worldwide(Globenewswire)
2023-10-11 20:01
Virion Therapeutics and Ocean Biomedical form joint venture supporting multi-national, first-in-humans clinical chronic hepatitis B study: now enrolling, with goal of a functional cure for a disease affecting 300+ million patients worldwide(Prnewswire)

Page 1 of 3

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.